Lord's Mark Industries eyes Rs 1,550 crore revenue target by FY2027

Lord's Mark Industries has set an ambitious revenue target of Rs 1,550 crore by the fiscal year ending March 2027, signaling aggressive expansion plans across its diagnostics and healthcare services portfolio.

The company has made substantial progress on its innovation front, completing patient trials for OneDNA, its proprietary genomic testing platform. The milestone follows clearance from the Indian Council of Medical Research (ICMR), a critical regulatory step that positions the platform for wider deployment in the Indian healthcare system.

Genomic testing has emerged as a crucial diagnostic tool in India's evolving healthcare landscape, offering personalized insights into genetic predispositions to various diseases. Lord's Mark's development of an indigenous platform addresses growing demand for advanced diagnostic capabilities while reducing reliance on imported testing solutions.

The company's revenue projections reflect confidence in both its existing diagnostic services and the commercial potential of emerging technologies like genomic testing. As India's healthcare sector increasingly embraces precision medicine, diagnostics players with in-house innovation capabilities are positioning themselves to capture growing market opportunities.

The ICMR approval and successful completion of patient trials underscore Lord's Mark's commitment to developing clinically validated diagnostic solutions tailored to the Indian healthcare market.